Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 696 of 5804
-
New hope for kids with painful mouth sores: drug trial launches
Disease control Recruiting nowThe aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New oral drug could offer hope for Tough-to-Treat eczema
Disease control CompletedThis was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug duo offers hope for Hard-to-Treat lymphoma
Disease control OngoingThis research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names of the study drugs involved in this study are: * Copanlisib * Venetoclax
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug cocktail aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior…
Phase: PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Tailored therapy could boost outcomes in elderly myeloma patients
Disease control Recruiting nowFrailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life p…
Sponsor: FengYan Jin • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could yearly Low-Energy laser replace daily eye drops for glaucoma?
Disease control Recruiting nowThe goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear…
Phase: PHASE3 • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Timing of chemo may boost survival in pancreatic cancer
Disease control OngoingThe PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 1…
Phase: PHASE3 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New transplant approach aims to tame Graft-Versus-Host disease
Disease control OngoingReduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RI…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Weekly shot helps people with obesity and prediabetes shed pounds and fix blood sugar
Disease control CompletedThis study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to control lymphoma without chemo
Disease control Recruiting nowThis phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of …
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
One-Time gene shot aims to tame rare copper disorder
Disease control OngoingThe objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following bac…
Phase: PHASE1, PHASE2 • Sponsor: Vivet Therapeutics SAS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Teen therapy aims to stop bipolar before it starts
Prevention OngoingInvestigators will conduct a confirmatory efficacy trial of Interpersonal and Social Rhythm Therapy (IPSRT) delivered via telehealth for offspring of bipolar parents (OBP; age 12-18, n=120) at elevated risk for BP onset via risk calculator score. All participants receive a baseli…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare tumor patients: AL102 drug trial launches
Disease control OngoingThe current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Phase: PHASE2, PHASE3 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
500 families join quest to unlock genetic secrets of miscarriage
Knowledge-focused Recruiting nowThe overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers
Disease control OngoingThis phase II clinical trial studies the effect of lenvatinib, pembrolizumab, and paclitaxel in treating patients with endometrial, epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). While all 3 study drugs are FDA approved, and 2-dru…
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New eczema cream shows promise in major trial
Symptom relief CompletedThis is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
Phase: PHASE3 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 26, 2026 13:45 UTC
-
Tight glucose control may preserve insulin-making cells in type 2 diabetes
Disease control OngoingDiabetes is a disorder of high blood glucose, that tends to get worse; over time, patients need more and more drugs. This pattern is caused by overwork of the body's insulin-producing β-cells, because patients' glucose levels are typically above normal; if the investigators kept …
Phase: NA • Sponsor: Foundation for Atlanta Veterans Education and Research, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could this treatment stop allergies before they start? new study in infants shows promise
Prevention CompletedThis is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subjects will be enrolled in a three-…
Phase: PHASE1, PHASE2 • Sponsor: Siolta Therapeutics, Inc. • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
Breakthrough trial aims to free kidney recipients from daily pills
Disease control OngoingThe goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the ab…
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a two-drug cocktail reverse liver scarring in NASH patients?
Disease control CompletedThis study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH). NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, whi…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC